abstract |
The present invention relates to obesity and related disorders: hyperglycemia, insulin resistance, development of type 2 diabetes and dyslipidemia, as well as fatty acid stimulants, hypoglycemia, insulin for skeletal muscle levels utilizing its reduced appetite function And an intestinal transport inhibitor of glucose by enterocytes. |